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WHAT THIS PAPER ADDS
 Gender differences in perceived health status do exist in postoperative PAD patients. Men and women experienced a disparate
change in overall health status from 3- to 5-year follow-up. Attention should be paid to gender disparities in postoperative PAD
patients, since men and women seem to experience different levels of HS over time.a r t i c l e i n f o
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Objectives: To investigate gender disparities in disease-speciﬁc health status (HS), 3- and 5-year post-
intervention in peripheral arterial disease (PAD) patients.
Design: Cohort study.
Methods: Data of 711 consecutively enrolled vascular surgery patients were collected in 11 hospitals in
The Netherlands in 2004. HS was assessed with the Peripheral Artery Questionnaire (PAQ). Our sample
included patients for whom it was possible to calculate a PAQ summary score at 3- and 5-year follow-up
(n ¼ 351).
Results: Women experienced worse physical health (52.1 vs. 62.0, P ¼ 0.012), greater disability (64.5 vs.
71.1, P ¼ 0.026), and worse overall HS (58.1 vs. 66.7, P ¼ 0.007) at 3-year follow-up than men. At 5-year
follow-up, however, male and female patients reported similar levels of HS. Mean changes in overall HS
from 3- to 5-year follow-up were signiﬁcantly different for men and women (4.12 vs. 1.69, P ¼ 0.014). In
male patients, overall HS was signiﬁcantly lower at 5-year follow-up compared to the 3-year follow-up
(66.7 vs. 62.6, P ¼ 0.001). In female patients, there was no signiﬁcant difference (58.1 vs. 59.8, P ¼ 0.393).
Conclusions: Men and women experience different levels of HS over time. Attention should be paid to
gender disparities in postoperative PAD patients.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral arterial disease (PAD) is a progressive athero-
thrombotic disease that has serious systemic consequences.1 As
a result, PAD is associated with increased all-cause and cardiovas-
cular mortality.2 This progressive atherosclerotic disease currently
affects approximately 16% of the general population aged 55 years
and older.1Verhagen).
ciety for Vascular Surgery. PublishePatients with PAD are faced not only with an increased risk of
mortality, but also with disability and reduced health status (HS).
Patient-reported outcomes, such as HS, are gaining increasing
recognition as indicators of the quality of care.3 Although both
generic and disease-speciﬁc measures are being used for this
purpose, disease-speciﬁc measures are more sensitive to detect
small but clinically meaningful differences in outcome as they tap
into patient limitations speciﬁc to the disease.4 In patients with
PAD, poor health-related quality of life (HRQoL) has been shown tod by Elsevier Ltd. All rights reserved.
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increasing number of studies in PAD patients are also focussing on
patient-reported outcomes. Particularly, patients who are older e
have more severe disease, experience more pain and have more co-
morbidities e are at risk for poor health status and HRQoL.6e12
However, patients undergoing vascular interventions seem to
experience improvements in HS and HRQoL.13e20
Given that arterial disease in terms of anatomy, physiology and
clinical manifestations has shown to differ according to gender,21
one might also expect that male and female PAD patients experi-
ence different levels of HS and HRQoL. A paucity of studies has
examined gender disparities in patient-centred outcomes in PAD.
Some studies reported worse HS and HRQoL in women as
compared to men,22e24 while others found the opposite result.25
However, none of these studies examined potential gender differ-
ences in HS or HRQoL after vascular repair. Given ﬁndings from
other vascular patient populations showing more postoperative
impairment in HS and HRQoL after surgical intervention in wom-
en,26e29 it might be expected that female PAD patients experience
worse HS and HRQoL after vascular repair.
The majority of studies examining differences in HS and HRQoL
in cardiovascular disease populations tend to have focussed on
differences in mean scores between groups rather than intra-
individual changes, which masks changes within individuals.30 A
distinct advantage of studying intra-individual changes over time is
that it provides information about patients who experience a clin-
ically meaningful decline in HS or HRQoL over time, which might
indicate that their treatment regimen needs to be adjusted in order
to prevent a further decline in HS and in order to enhance
secondary prevention.
In the current study, we investigated gender disparities in
disease-speciﬁc HS, measured with the Peripheral Artery Ques-
tionnaire (PAQ), 3- and 5-years post-intervention in a consecutive
cohort of PAD patients undergoing vascular surgery, using both
a between-group and an intra-individual approach.
Methods
Design and study population
This study was based on data from 711 PAD patients enrolled at
11 hospitals across The Netherlands between May and December
2004, who were followed up for 5 years after vascular surgery. The
study was part of the Dutch Euro Heart Survey Programme. All
patients were seen at the participating vascular surgery depart-
ments and were undergoing non-cardiac vascular surgery (endo-
vascular or open procedures). Endovascular procedures included
aortic endograft procedures and peripheral angioplasties with or
without stenting. Open procedures included elective abdominal
aortic surgery, carotid endarterectomy or infrainguinal arterial
reconstruction. Local ethics committees of the involved centres all
approved the study, and all patients provided informed consent for
follow-up contact. After 3 and 5 years, information on the patient’s
vital status was obtained from the civil registries. All survivors were
contacted to ﬁll in the PAQ. Our sample only included PAD patients
for whom it was possible to calculate a PAQ summary score at 3-
and 5-year follow-up.
Measures
Demographic and clinical variables
Information on demographics and the medical history was
abstracted from patients’ medical records and questionnaires at
the time of procedure. Information included age, ischaemic heart
disease (IHD), angina pectoris, myocardial infarction, previousrevascularisation, heart failure, stroke or trans-ischaemic attack
(TIA), obesity, hypertension, diabetes mellitus, renal insufﬁ-
ciency, chronic obstructive pulmonary disease (COPD), endovas-
cular procedure, open procedure, aspirin, beta-blockers and
statins.
Disease-speciﬁc HS
To measure disease-speciﬁc HS, the Dutch translation of the
disease-speciﬁc PAQ was used.31 The PAQ quantiﬁes physical limi-
tations, symptoms (frequency, severity and recent change over
time), quality of life, social function and treatment satisfaction.32
The PAQ has shown to be a reliable, valid and responsive measure
with good clinical validity.31,32 The instrument consists of 20 items,
with one item identifying the most symptomatic leg and the other
items rated on variable Likert scales with equidistant response
gradations. The Dutch version of the PAQ is composed of three
overarching domains: physical limitation, perceived disability and
treatment satisfaction.31 In this study, treatment satisfaction was
left out, because it is not included in the summary score. Since the
response categories are different across items, standardised scoring
algorithms are applied to obtain domain scores ranging from 0 to
100, with higher scores indicating better HS. A summary score is
calculated as the average of the physical limitation and perceived
disability domain scores.
Change scores on the PAQ domains and the PAQ summary score
are deﬁned as the difference between the 3- and 5-year follow-up
scores. A change of 8 points on the 100-point PAQ domain scales
and summary scale was used to deﬁne a clinically meaningful
change. This 8% change was considered to represent a clinically
meaningful difference according to Sloan et al.,33 who concluded
that a medium effect size corresponded to a change of 8% of the
range of the instrument used to assess HS. In addition, Cohen
deﬁned a medium effect size as 50% of the standard deviation (SD)
of an instrument, which is 16.7% of any scale on the basis of the fact
that 99% of observations fall within 3 SDs of the mean. Change
scores of e8 points were deﬁned as a clinically meaningful
decline, and all other change scores as ‘not declined’.
Statistical analysis
Baseline demographic and clinical characteristics for male and
female patients were compared using Pearson’s chi-square and
Student’s t-tests. Absolute scores for Physical Limitation, Perceived
Disability and PAQ summary at 3- and 5-year follow-up and change
scores from 3- to 5-year follow-up are listed as means with 95%
conﬁdence intervals (CI)s for male and female patients separately.
Comparisons of the mean scores betweenmale and female patients
at 3- and 5-year follow-up and the mean change scores from 3- to
5-year follow-up were performed using Student’s t-tests for inde-
pendent samples. To compare mean Physical Limitation, Perceived
Disability and PAQ summary scores from 3- to 5-year follow-up
within both sexes, Student’s t-tests for paired samples were used.
Furthermore, the proportion (%) of patients that reported clinically
meaningful declines (‘declined’) and the proportion that did not
make clinically meaningful declines (‘not declined’) on Physical
Limitation, Perceived Disability and PAQ summary are shown for
both sexes separately. Comparisons of the proportion of male and
female patients that were classiﬁed as ‘declined’ and ‘not declined’
on Physical Limitation, Perceived Disability and PAQ summary were
made using Pearson’s chi-square tests. General linear mixed model
(GLMM) analyses were used to analyse changes in overall HS over
time, with gender as a factor and all other baseline characteristics
as covariates. This type of statistical analysis was chosen because it
models group means as ﬁxed effects while simultaneously
modelling individual subject variables as random effects.34 The
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clinical risk factors, type of procedure and the interaction between
follow-up and gender. An autoregressive structure was used.
Sensitivity analyses were performed to adjust for the entity of PAD
(i.e., peripheral arterial occlusive disease of the lower limbs,
abdominal aortic aneurysms and carotid stenosis). For all tests,
a P-value <0.05 was considered signiﬁcant. All statistical analyses
were performed using SPSS 17.0 statistical software (SPSS Inc.,
Chicago, IL, USA).
Results
Responders versus non-responders
The original sample consisted of 711 PAD patients undergoing
vascular surgery at baseline (Fig. 1). This sample consisted of 496
men (69.8%) and 215 women (30.2%). After 5 years of follow-up,
200 patients had died, of whom 144 (72.0%) were male and 56
(28%) were female. Twenty-ﬁve patients (13 men, 12 women) were
lost to follow-up. All 486 surviving patients were sent question-
naires, of which 390 responded (80.2% response rate). The ﬁnal
sample included 351 patients (72.2%), for whom both PAQ
summary scores (at 3- and 5-year follow-up) could be computed.
This sample consisted of 251 men (71.5%) and 100 women (28.5%).
To investigate response bias, responders were compared with non-
responders. No systematic differences were found on baseline
characteristics.Figure 1. FlowchartBaseline characteristics
Baseline characteristics of the total sample and stratiﬁed by
gender are listed in Table 1. Themean age of patients was 64.8 9.6
years. Men had a signiﬁcantly higher prevalence of IHD (31.9% vs.
16.0%, P ¼ 0.003), myocardial infarction (17.5% vs. 8.0%, P ¼ 0.023)
and previous revascularisation (18.7% vs. 7.0%, P¼ 0.006) compared
to women. In addition, men more often underwent an open
vascular procedure (53.8% vs. 30.0%, P < 0.001) compared to
women.
HS 3- and 5-years post-intervention
The mean Physical Limitation, Perceived Disability and PAQ
summary score at 3- and 5-years post-intervention are shown in
Table 2 and Fig. 2A and B. Women experienced poorer physical
health (52.1 vs. 62.0, P ¼ 0.012), greater perceived disability (64.5
vs. 71.1, P ¼ 0.026) and worse overall HS (58.1 vs. 66.7, P ¼ 0.007) at
3-year follow-up as compared with men. At 5-year follow-up,
however, there were no statistically signiﬁcant differences
between men and women on HS. Generally, the total cohort of PAD
patients experienced poorer physical health (55.7 vs. 59.1,
P¼ 0.005) and overall HS (61.8 vs. 64.3, P¼ 0.022) at 5-year follow-
up compared to 3-year follow-up. Male patients reported not only
poorer physical health (56.9 vs. 62.0, P¼ 0.002) and overall HS (62.6
vs. 66.7, P ¼ 0.001), but also greater perceived disability (68.4 vs.
71.1, P ¼ 0.032) at 5-year follow-up compared to 3-year follow-up.FU, follow-up.
Table 1
Baseline characteristics for the total population and stratiﬁed by gender.a
Total Men Women P-value
n 351 (100) 251 (71.5) 100 (28.5)
Demographics
Mean age (SD) 64.8 (9.6) 65.1 (9.0) 63.9 (11.0) 0.331
Cardiovascular history
IHD 96 (27.4) 80 (31.9) 16 (16.0) 0.003
Angina pectoris 52 (14.8) 41 (16.3) 11 (11.0) 0.204
Myocardial infarction 52 (14.8) 44 (17.5) 8 (8.0) 0.023
Previous revascularization 54 (15.4) 47 (18.7) 7 (7.0) 0.006
Heart failure 8 (2.3) 4 (1.6) 4 (4.0) 0.173
Stroke or TIA 46 (13.1) 36 (14.3) 10 (10.0) 0.277
Clinical risk factors
Obesity 39 (11.1) 26 (10.4) 13 (13.0) 0.477
Hypertension 135 (38.5) 101 (40.2) 34 (34.0) 0.278
Diabetes mellitus 62 (17.7) 47 (18.7) 15 (15.0) 0.409
Renal insufﬁciency 18 (5.1) 15 (6.0) 3 (3.0) 0.254
COPD 34 (9.7) 27 (10.8) 7 (7.0) 0.283
Surgical procedure
Endovascular 200 (57.0) 125 (49.8) 75 (75.0) <0.001
Open 165 (47.0) 135 (53.8) 30 (30.0) <0.001
Medication use
Aspirin 263 (74.9) 187 (74.5) 76 (76.0) 0.770
Beta-blockers 175 (49.9) 131 (52.2) 44 (44.0) 0.166
Statins 218 (62.1) 159 (63.3) 59 (59.0) 0.449
n, number; SD, standard deviation; IHD, ischaemic heart disease; TIA, transient
ischaemic attack; COPD, chronic obstructive pulmonary disease.
a Presented as n (%), unless otherwise indicated.
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both follow-up moments.
Changes in HS
The mean change scores on Physical Limitation, Perceived
Disability and PAQ summary from 3- to 5-years post-intervention
are shown in Table 3 and Fig. 3. Mean changes in overall HS from
3- to 5-year follow-up were signiﬁcantly different for men and
women (4.12 vs. 1.69, P ¼ 0.014).
Furthermore, a higher but non-signiﬁcant percentage of men
compared to women experienced a clinically meaningful increaseTable 2
PAQ domain and summary scores 3- and 5-years post-intervention for male and
female PAD patients.
Total n ¼ 351 Men n ¼ 251 Women n ¼ 100 P-value
Mean (95% CI) Mean (95% CI) Mean (95% CI)
3-years follow-upa
Physical Limitation
Score 59.12
(53.61e64.63)
61.98
(55.44e68.52)
52.13
(42.19e62.07)
0.012
Perceived Disability
Score 69.24
(65.04e73.44)
71.09
(66.21e75.97)
64.46
(56.40e72.52)
0.026
Summary Score
Score 64.28
(59.72e68.84)
66.74
(61.38e72.10)
58.12
(49.72e66.52)
0.007
5-years follow-upb
Physical Limitation
Score 55.68
(50.40e60.96)c
56.85
(50.55e63.15)c
52.57
(42.91e62.23)
0.273
Perceived Disability
Score 67.20
(63.08e71.32)
68.41
(63.54e73.28)c
64.15
(56.50e71.80)
0.143
Summary Score
Score 61.82
(57.37e66.27)c
62.62
(57.30e67.94)c
59.81
(51.67e67.95)
0.369
n, number; 95% CI, 95% conﬁdence interval; PAQ, peripheral arterial questionnaire.
a Missing scores on PAQ ranging from 0 to 7%.
b Missing scores on PAQ ranging from 0 to 11%.
c Signiﬁcant decrease in PAQ domain or summary score from 3- to 5-years post-
intervention.in perceived disability (31.5% vs. 23.0%, P ¼ 0.115) and a decline in
overall HS (35.5% vs. 26.0%, P ¼ 0.088) over time, as indicated by
a change of e8 points on Perceived Disability and PAQ summary
from 3- to 5-year follow-up. A similar percentage of men and
women experienced a clinically meaningful decline in physical
health from 3- to 5-year follow-up (P ¼ 0.906).
GLMM analysis showed a signiﬁcant interaction effect of follow-
up moment  gender for overall HS (b ¼ 5.81, P ¼ 0.014), which
signiﬁes that male and female patients experienced disparate
changes in overall HS from 3- to 5-years post-intervention. Sepa-
rate analyses for male and female patients were therefore con-
ducted (Table 4). In male patients, analysis showed that overall HS
was signiﬁcantly lower at 5-year follow-up compared to the 3-year
follow-up (b ¼ 4.12, P ¼ 0.001). Moreover, older men reported
lower levels of HS than younger men (b ¼ 0.43, P ¼ 0.017). Like-
wise, male patients with concomitant diabetes experienced worse
HS than male patients without diabetes (b ¼ 8.30, P ¼ 0.038). In
female patients, the effect of follow-up moment was non-
signiﬁcant, which indicates that women reported similar levels of
HS at 3- and 5-year follow-up. However, overall HS was lower for
older women than for younger women (b ¼ 0.53, P ¼ 0.018).
Sensitivity analyses adjusting for the entity of PAD showed similar
results. In male patients with peripheral arterial occlusive disease
of the lower limbs, overall HS was predicted by follow-up moment
(b ¼ 4.22, P ¼ 0.010), age (b ¼ 0.64, P ¼ 0.004) and IHD
(b¼8.38, P¼ 0.049). The effect of diabetes was non-signiﬁcant. In
female patients with peripheral arterial occlusive disease of the
lower limbs, overall HS was predicted by age (b ¼ 0.60, P ¼ 0.013)
and diabetes (b ¼ 16.25, P ¼ 0.033).
Discussion
To ourknowledge, this is theﬁrst prospective study that focussed
on gender disparities in disease-speciﬁc HS in a consecutive cohort
of postoperative PAD patients. Generally, women experienced
poorer HS as compared to men at 3-year follow-up, while at 5-year
follow-up male and female patients reported similar levels of HS.
Moreover, a higher but non-signiﬁcant percentage of men
compared towomen experienced a clinicallymeaningful increase in
perceived disability and a decline in overall HS from 3- to 5-years
post-intervention. Furthermore, men and women experienced
a disparate change in overall HS from 3- to 5-year follow-up.
At 3-years post-intervention, women reported poorer HS as
compared to men, with differences in physical health, perceived
disability and overall HS being statistically signiﬁcant and clinically
relevant. This result is consistent with an earlier ﬁnding, demon-
strating that female PAD patients are more likely to report poor
HRQoL in the long term.24 A number of studies including other
vascular patient populations also found female sex to be associated
with inferior postoperative HS.35e38 In our study, however, at 5-
years post-intervention male and female patients experienced
similar levels of HS. While women reported comparable HS at both
follow-up moments, men rated their HS lower at 5-years post-
intervention. The reason for this result is not well understood,
but it may be attributed to the similar age of patients at time of
treatment and the different life expectancies formen andwomen at
the age of about 65.
Investigating group changes showed that women barely
perceived a change in overall HS from 3- to 5-year follow-up, while
in the same period of time men experienced a decline. However,
clinically meaningful individual changes cannot be extracted from
group changes, since one cannot assume that each individual
experienced the group mean differential.30 Therefore, we also
deﬁned intra-individual HS changes in male and female patients
from 3- to 5-year follow-up. Our results showed that a higher but
Figure 2. (A) Mean scores on the PAQ domains and summary for male and female PAD patients at 3-years follow-up. (B) Mean scores on the PAQ domains and summary for male
and female PAD patients at 5-years follow-up.
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Table 3
Mean change scores on PAQ domains and summary for male and female PAD patients and proportions stratiﬁed by gender and ‘declined’ vs ‘not declined’.a
PAQ Change in PAQ scoresb,c
Total n ¼ 351 Men n ¼ 251 Women n ¼ 100 P-value
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Physical Limitation
Score 3.47 (7.11 to 0.17) 4.40 (8.59 to 0.21) 1.15 (8.38 to 6.08) 0.235
Declined 34.5 (29.7e39.6) 34.7 (29.0e40.7) 34.0 (25.4e43.7) 0.906d
Not declined 65.5 (60.4e71.0) 65.3 (59.3e71.1) 66.0 (56.3e74.6)
Perceived Disability
Score 1.81 (4.95 to 1.33) 2.59 (6.35 to 1.17) 0.21 (5.46 to 5.88) 0.215
Declined 29.1 (24.6e34.0) 31.5 (26.0e37.5) 23.0 (15.8e32.2) 0.115
Not declined 70.9 (66.0e75.5) 68.5 (62.5e74.0) 77.0 (67.8e84.2)
Summary Score
Score 2.46 (5.84 to 0.92) 4.12 (8.10 to 0.14) 1.69 (4.55 to 7.93) 0.014
Declined 32.8 (28.1e37.8) 35.5 (29.8e41.6) 26.0 (18.4e35.4) 0.088
Not declined 67.2 (62.2e71.9) 64.5 (58.4e70.2) 74.0 (64.6e81.6)
n, number; 95% CI, 95% conﬁdence interval; PAQ, peripheral arterial questionnaire.
a Presented as % (95% CI), unless otherwise indicated.
b The change in PAQ domain and summary scores from 3- to 5-year follow-up (5-years post-intervention minus 3-years post-intervention scores). SD, standard deviation;
Declined, number and percentage of patients with a change score of  8; Not declined, number and percentage of patients with a change score of > 8.
c Missing change scores on PAQ ranging from 0 to 13%.
d To test whether male and female patients have different outcomes (declined vs not declined) on PAQ domains and summary.
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enced a clinically meaningful increase in perceived disability and
a decline in overall HS from 3- to 5-year follow-up. Additional
analyses demonstrated that male and female patients did perceive
a disparate change in overall HS from 3- to 5-years post-
intervention. Whereas postoperative HS in men was predicted by
follow-up moment (worse HS at 5-years post-intervention), this
was not the case for women. Older age was predictive of worse HS
in both sexes and concomitant diabetes predicted lower levels of HS
in male PAD patients and female patients with peripheral arterial
occlusive disease of the lower limbs. Furthermore, IHD was
predictive of worse HS in male patients with peripheral arterialFigure 3. Mean PAQ domain and summary change scores for male and female PAD paocclusive disease of the lower limbs. These results are consistent
with previous ﬁndings, demonstrating that PAD patients who are
older and those with co-morbid diabetes and IHD are at greater risk
of experiencing lower levels of HS and HRQoL.10,12,39e41 The
aforementioned results demonstrate that it is necessary to inves-
tigate intra-individual changes in HS in addition to group mean
changes, since it yields valuable information for clinical practice
that cannot be extracted from between-group comparisons.
The ﬁndings of the current study should be interpreted with
some caution. First, we had no information on HS at baseline.
Consequently, we do not know whether male and female patients
already displayed differences in HS prior to vascular surgery.tients. Negative change scores signify a decline in HS from 3- to 5-year follow-up.
Table 4
General linear mixed model effects for PAQ summary.
Effect Men Women Men Women
b (95% CI) P-value
Intercept 39.66
(3.30 to 82.61)
50.10
(7.34 to 107.54)
0.070 0.087
Follow-up 4.12
(1.64e6.60)
1.69
(5.61 to 2.23)
0.001 0.393
Age 0.43
(0.78 to 0.08)
0.53
(0.96 to 0.09)
0.017 0.018
IHD 6.10
(.059 to 12.78)
5.52
(9.78 to 20.82)
0.074 0.476
Heart failure 13.72
(10.12 to 37.57)
10.74
(16.69 to 38.18)
0.258 0.439
Stroke or TIA 8.30
(0.19 to 16.78)
9.55
(28.93 to 9.83)
0.055 0.330
Obesity 6.72
(3.45 to 16.89)
9.93
(6.11 to 25.97)
0.194 0.222
Hypertension 4.75
(11.09 to 1.59)
7.16
(3.96 to 18.28)
0.142 0.204
Diabetes 8.30
(0.46e16.14)
10.29
(3.87 to 24.44)
0.038 0.152
Renal
insufﬁciency
10.63
(1.88 to 23.15)
16.05
(13.19 to 45.29)
0.096 0.278
COPD 5.58
(4.17 to 15.34)
0.77
(21.18 to 19.64)
0.261 0.941
Endo 2.53
(3.58 to 8.64)
0.29
(13.23 to 13.81)
0.416 0.966
IHD, ischaemic heart disease; TIA, transient ischaemic attack; COPD, chronic
obstructive pulmonary disease; Endo ¼ type of intervention.
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from pre- to post-intervention. Second, since participants who
completed HS questionnaires at 3- and 5-year follow-up probably
comprise a relatively healthy subpopulation, our ﬁndingsmight not
generalise to all PAD patients. Death might have led to a selection
bias, with the possibility that these patients would have experi-
enced poorer HS, given that HS has proven to be an independent
predictor of prognosis in PAD patients.5
The study also has several strengths. To measure HS we used the
PAQ, a disease-speciﬁc instrument. As it taps into limitations
speciﬁc to PAD, it is a sensitive measure with respect to detecting
small but clinically meaningful differences in HS.4 In addition,
besides deﬁning group mean changes, we examined intra-
individual changes by determining the percentage of male and
female patients who experienced a clinically meaningful decline in
HS from 3- to 5-year follow-up. Moreover, we conducted GLMM
analyses that acknowledge both group and individual differences.
Furthermore, we focussed on gender disparities in perceived HS,
which is of clinical importance since arterial disease in terms of
anatomy, physiology and clinical manifestations has shown to differ
according to sex.21
In conclusion, this study shows that gender differences in
perceived HS do exist in postoperative PAD patients. Future studies
are warranted to replicate the ﬁndings of the current study.
Furthermore, we encourage other researchers to examine intra-
individual changes in HS in addition to group mean changes, as it
allows us to get a better estimate of the likelihood that patients will
beneﬁt from a vascular intervention. Finally, attention should be
paid to gender disparities in postoperative PAD patients, since men
and women seem to experience different levels of HS over time.
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